Analysts' Opinions Are Mixed on These Financial Stocks: Victory Capital Holdings (VCTR) and QBE Insurance Group Limited (OtherQBEIF)
Analysts have been eager to weigh in on the Financial sector with new ratings on Victory Capital Holdings (VCTR – Research Report) and QBE Insurance Group Limited (QBEIF – Research Report).
Protect Your Portfolio Against Market Uncertainty
Victory Capital Holdings (VCTR)
Barclays analyst Benjamin Budish maintained a Hold rating on Victory Capital Holdings on May 9 and set a price target of $62.00. The company's shares closed last Friday at $59.14.
According to TipRanks.com, Budish is a 5-star analyst with an average return of 15.4% and a 71.0% success rate. Budish covers the Financial sector, focusing on stocks such as Virtus Investment Partners, Intercontinental Exchange, and Apollo Global Management.
Currently, the analyst consensus on Victory Capital Holdings is a Moderate Buy with an average price target of $68.86, a 16.2% upside from current levels. In a report issued on April 29, J.P. Morgan also maintained a Hold rating on the stock with a $62.00 price target.
QBE Insurance Group Limited (QBEIF)
Morgan Stanley analyst Andrei Stadnik maintained a Buy rating on QBE Insurance Group Limited today and set a price target of A$24.60. The company's shares closed last Wednesday at $13.50.
According to TipRanks.com, Stadnik is a 4-star analyst with an average return of 7.1% and a 54.4% success rate. Stadnik covers the Financial sector, focusing on stocks such as Insurance Australia Group Limited, Macquarie Group Limited, and Insignia Financial Ltd.
Currently, the analyst consensus on QBE Insurance Group Limited is a Strong Buy with an average price target of $15.12, representing a 12.0% upside. In a report issued on April 30, Goldman Sachs also maintained a Buy rating on the stock with a A$25.00 price target.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Insider
4 hours ago
- Business Insider
Analysts Offer Insights on Consumer Cyclical Companies: Five Below (FIVE) and Autoliv (ALV)
Companies in the Consumer Cyclical sector have received a lot of coverage today as analysts weigh in on Five Below (FIVE – Research Report) and Autoliv (ALV – Research Report). Confident Investing Starts Here: Five Below (FIVE) Barclays analyst Seth Sigman maintained a Hold rating on Five Below on June 5 and set a price target of $120.00. The company's shares closed last Friday at $127.35. According to Sigman 's ranking currently consits of 0 on a 0-5 ranking scale, with an average return of -7.0% and a 53.9% success rate. Sigman covers the NA sector, focusing on stocks such as Driven Brands Holdings, Floor & Decor Holdings, and Advance Auto Parts. Five Below has an analyst consensus of Moderate Buy, with a price target consensus of $118.63, which is a -7.0% downside from current levels. In a report issued on May 28, Citi also maintained a Hold rating on the stock with a $121.00 price target. Autoliv (ALV) Kepler Capital analyst Alexandre Raverdy maintained a Buy rating on Autoliv on June 5 and set a price target of $100.00. The company's shares closed last Friday at $105.62. According to Raverdy is ranked #5408 out of 9607 analysts. Autoliv has an analyst consensus of Strong Buy, with a price target consensus of $111.31, a 4.8% upside from current levels. In a report issued on May 28, UBS also maintained a Buy rating on the stock with a $123.00 price target.
Business Insider
3 days ago
- Business Insider
Analysts Offer Insights on Industrial Goods Companies: Performance Shipping (PSHG) and Sterling Construction (STRL)
There's a lot to be optimistic about in the Industrial Goods sector as 2 analysts just weighed in on Performance Shipping (PSHG – Research Report) and Sterling Construction (STRL – Research Report) with bullish sentiments. Confident Investing Starts Here: Performance Shipping (PSHG) In a report issued on May 30, Tate Sullivan from Maxim Group reiterated a Buy rating on Performance Shipping, with a price target of $5.00. The company's shares closed last Tuesday at $1.60, close to its 52-week low of $1.48. According to Sullivan 's ranking currently consits of 0 on a 0-5 ranking scale, with an average return of -9.9% and a 38.7% success rate. Sullivan covers the Industrial Goods sector, focusing on stocks such as United Maritime Corp., Seanergy Maritime, and BWX Technologies. The the analyst consensus on Performance Shipping is currently a Hold rating. William Blair analyst Louie DiPalma maintained a Buy rating on Sterling Construction today. The company's shares closed last Tuesday at $194.23, close to its 52-week high of $206.07. According to DiPalma has 0 stars on 0-5 stars ranking scale with an average return of -11.7% and a 60.6% success rate. DiPalma covers the Technology sector, focusing on stocks such as Palantir Technologies, Science Applications, and BigBearai Holdings. The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Sterling Construction with a $205.00 average price target.
Business Insider
3 days ago
- Business Insider
Analysts Offer Insights on Healthcare Companies: Exact Sciences (EXAS) and Arcus Biosciences (RCUS)
There's a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Exact Sciences (EXAS – Research Report) and Arcus Biosciences (RCUS – Research Report) with bullish sentiments. Confident Investing Starts Here: Exact Sciences (EXAS) In a report issued on June 2, Brandon Couillard from Wells Fargo maintained a Buy rating on Exact Sciences, with a price target of $68.00. The company's shares closed last Tuesday at $54.84. According to Couillard is a 5-star analyst with an average return of 14.1% and a 59.5% success rate. Couillard covers the Healthcare sector, focusing on stocks such as Maravai Lifesciences Holdings, Bio-Rad Laboratories, and Myriad Genetics. Exact Sciences has an analyst consensus of Strong Buy, with a price target consensus of $69.94. In a report issued on June 2, Daina Graybosch from Leerink Partners maintained a Buy rating on Arcus Biosciences, with a price target of $46.00. The company's shares closed last Tuesday at $10.03. According to Graybosch has currently 0 stars on a ranking scale of 0-5 stars, with an average return of -15.0% and a 33.3% success rate. Graybosch covers the Healthcare sector, focusing on stocks such as Turnstone Biologics Corp., Werewolf Therapeutics, and Century Therapeutics. Currently, the analyst consensus on Arcus Biosciences is a Strong Buy with an average price target of $27.88, representing a 203.4% upside. In a report issued on May 23, Barclays also maintained a Buy rating on the stock with a $14.00 price target.
